Application of the AMLprofiler diagnostic microarray in the South African setting

Show simple item record

dc.contributor.author Kappala, S.S.
dc.contributor.author Alessandrini, Marco
dc.contributor.author Matlhako, T.
dc.contributor.author Beltchev, E.
dc.contributor.author Pool, Roger
dc.contributor.author Pepper, Michael Sean
dc.date.accessioned 2017-11-30T06:14:16Z
dc.date.available 2017-11-30T06:14:16Z
dc.date.issued 2017-11-07
dc.description.abstract Acute myeloid leukemia (AML) is characterized by proliferation of the myeloid lineage and accumulation of immature hematopoietic cells in the bone marrow and is typified by marked heterogeneity both in response to treatment and survival. AMLprofiler is a qualitative in vitro diagnostic microarray incorporating seven molecular biomarkers used to diagnose and predict posttherapy survival rates. In this study, we compared AMLprofiler to routine AML diagnostic methodologies employed in South Africa, focusing on consistency of the results, cost, and time to result. RNA was isolated from bone marrow and peripheral blood samples from patients with de novo AML and was processed using Affymetrix Gene Profiling Reagent kits. The results from AMLprofiler and standard methodologies were highly comparable. In addition, many samples were determined to be positive for biomarkers not routinely investigated in South Africa, namely, CEBPA double mutants, NPM1 variants, and altered expression levels of BAALC and EVI1. 38% of samples presented with no positive biomarker; AMLprofiler nonetheless enabled 26% of AML patients to be classified into either favorable or poor prognostic categories. This study highlights the comprehensive nature of the microarray. Decreased time to result and refinement of risk stratification are notable benefits. en_ZA
dc.description.department Haematology en_ZA
dc.description.department Immunology en_ZA
dc.description.librarian am2017 en_ZA
dc.description.sponsorship The University of Pretoria (Institute for Cellular and Molecular Medicine and Vice Chancellor’s post-doctoral fellowship), the National Health Laboratory Services Research Trust, the South African Medical Research Council (Category 1 University Flagship and Extramural Stem Cell Unit grants), and the National Research Foundation of South Africa. en_ZA
dc.description.uri https://www.hindawi.com/journals/sci en_ZA
dc.identifier.citation Kappala, S.S. ... et al. 2017, 'Application of the AMLprofiler diagnostic microarray in the South African setting', Stem Cells International, vol. 2017, art. no. 2560191, pp. 1-8. en_ZA
dc.identifier.issn 1687-966X (print)
dc.identifier.issn 1687-9678 (online)
dc.identifier.other 10.1155/2017/2560191
dc.identifier.uri http://hdl.handle.net/2263/63384
dc.language.iso en en_ZA
dc.publisher Hindawi Publishing Corporation en_ZA
dc.rights © 2017 S. S. Kappala et al. This is an open access article distributed under the Creative Commons Attribution License. en_ZA
dc.subject Myeloid lineage en_ZA
dc.subject Treatment en_ZA
dc.subject Diagnose en_ZA
dc.subject Acute myeloid leukemia (AML) en_ZA
dc.subject Adult patients en_ZA
dc.subject Nucleophosmin mutations en_ZA
dc.subject Cytogenetics en_ZA
dc.subject Binding protein-α (C/EBPα) en_ZA
dc.title Application of the AMLprofiler diagnostic microarray in the South African setting en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record